[
  {
    "question": "Question about the Papez circuit?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "The Papez circuit is a neural pathway critical for the regulation of emotions and memory. It is traditionally described as a loop connecting the hippocampus, fornix, mammillary bodies, anterior thalamic nuclei, and the cingulate gyrus. Disruption in any component of the Papez circuit can impair the consolidation and retrieval of memories. Modern studies have shown that while the circuit is primarily involved in memory functions, it also has roles in emotional processing via limbic connections. Clinically, lesions affecting components of the Papez circuit may present with anterograde amnesia and other memory disturbances. A thorough understanding is necessary when evaluating patients with memory impairment to differentiate it from other causes like Alzheimer\u2019s disease. Diagnosis is based on neuroanatomical localization supported by neuroimaging (MRI). Differential diagnoses include other limbic system disorders and neurodegenerative diseases. Distinguishing the Papez circuit involvement often requires correlating clinical findings with imaging evidence of structural lesions. There is no direct treatment for a lesion solely confined to the Papez circuit; management is typically aimed at the underlying cause such as stroke, tumor, or traumatic brain injury. For example, in the case of an ischemic event, standard stroke protocols are followed. In pregnant or lactating patients, non-ionizing imaging modalities are preferred and any pharmacotherapy is chosen with fetal safety in mind. Due to the incomplete nature of the question options, the analysis focuses on the fact that the correct option for a Papez circuit question should list the classic components (hippocampus, fornix, mammillary bodies, anterior thalamic nuclei, and cingulate gyrus). Option A is presumed correct if it accurately reflects these components. Incorrect options may erroneously include structures like the amygdala or misattribute motor functions. 1. Remember that the Papez circuit is essential for memory consolidation. 2. It is a closed neural loop involving key limbic structures. 3. Accurate anatomical knowledge is crucial to differentiate it from other neural circuits. Recent literature emphasizes the intricate connections within the limbic system, with advanced neuroimaging techniques further delineating the role of the Papez circuit in cognitive and emotional regulation. Updated guidelines continue to refine the neuroanatomical boundaries of this circuit.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "What is the second most common cause of dementia:",
    "option_a": "vascular dementia.",
    "option_b": "Dementia with Lewy bodies",
    "option_c": "FTD",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Dementia is most frequently caused by Alzheimer\u2019s disease, and the second most common cause is vascular dementia. Vascular dementia results from cerebrovascular disease and is characterized by a stepwise decline in cognitive function. Vascular dementia arises from cumulative ischemic damage due to infarcts and chronic small vessel disease. The resultant brain injury leads to cognitive deficits, often in a stepwise fashion corresponding to new vascular events. Patients with vascular dementia typically present with a history of vascular risk factors (hypertension, diabetes, hyperlipidemia) and may exhibit sudden declines following strokes or transient ischemic attacks, in contrast to the gradual decline seen in Alzheimer\u2019s disease. Diagnosis involves a combination of clinical history, neuropsychological testing, and neuroimaging (CT/MRI). Differential diagnoses include Alzheimer\u2019s disease (which has a more insidious onset), Dementia with Lewy bodies (associated with parkinsonism and visual hallucinations), and frontotemporal dementia (which presents with prominent behavioral or language changes). Management is focused on controlling vascular risk factors such as hypertension, diabetes, and hyperlipidemia, along with antiplatelet therapy when indicated. Cognitive rehabilitation and supportive care are also important. In pregnant or lactating patients, management of vascular risk factors requires careful balancing of maternal benefits against fetal risks, with medications chosen based on safety profiles and guidelines. Option A, vascular dementia, is correct as epidemiological studies consistently show it as the second most common cause of dementia after Alzheimer\u2019s disease. Options B (Dementia with Lewy bodies) and C (frontotemporal dementia) are less common in prevalence compared to vascular dementia. 1. Vascular dementia should be suspected in patients with a stepwise cognitive decline and significant vascular risk factors. 2. Neuroimaging is key to demonstrating infarcts and white matter changes. 3. Aggressive risk factor management can slow progression. Recent updates in vascular dementia research emphasize the role of multimodal neuroimaging in early diagnosis and improved stratification of vascular risk. Guidelines now underscore aggressive management of modifiable risk factors to prevent new cerebrovascular events.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient with cognitive decline, also mentioned urinary incontinence & magnetic gate:",
    "option_a": "Parkinson disease.",
    "option_b": "NPH",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Normal Pressure Hydrocephalus (NPH) is characterized by a clinical triad of cognitive decline, gait disturbance (often described as a \u2018magnetic gait\u2019), and urinary incontinence. This triad distinguishes it from other neurodegenerative conditions. NPH is thought to arise from an imbalance in cerebrospinal fluid (CSF) dynamics, particularly impaired CSF absorption, leading to ventricular enlargement without corresponding increases in intracranial pressure. The enlarged ventricles exert pressure on periventricular white matter tracts, affecting gait and cognitive function. Patients with NPH typically exhibit a magnetic gait in which they have difficulty initiating steps, along with a broad-based, shuffling walk. Cognitive decline in NPH is generally subcortical, with slowing of thought processes and executive dysfunction. Urinary incontinence is another key feature that helps in differentiating NPH from other dementias such as Parkinson disease. Diagnosis involves a combination of clinical evaluation and radiological evidence. Brain MRI typically shows ventriculomegaly with relatively preserved cortical size. Differential diagnoses include Parkinson disease, Alzheimer\u2019s disease, and vascular dementia. A high-volume lumbar puncture (CSF tap test) can help confirm the diagnosis when gait improves transiently post-procedure. The first-line treatment for NPH is a CSF drainage test (large-volume lumbar puncture) to assess potential reversibility of symptoms. If improvement is observed, a ventriculo-peritoneal (VP) shunt is typically recommended as definitive therapy. In pregnant or lactating patients, the decision for surgical intervention must balance maternal neurological improvement with surgical and anesthetic risks, and non-surgical management may be preferred if the symptoms are not severe. Option B (NPH) is correct because the combination of cognitive decline, urinary incontinence, and a magnetic gait is the classic presentation of normal pressure hydrocephalus. Option A (Parkinson disease) is less likely, as Parkinson\u2019s typically presents with rest tremor, rigidity, and bradykinesia without the triad seen in NPH. 1. Always consider NPH in elderly patients with a triad of gait instability, cognitive impairment, and incontinence. 2. A CSF tap test is a valuable diagnostic tool for predicting response to shunting. 3. Early diagnosis can lead to reversible improvement in function. Current guidelines stress the importance of early recognition of NPH because timely shunting can markedly improve patient outcomes. Recent studies have also focused on optimizing shunt technology and minimizing complications associated with surgical intervention.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Case of hyperphagia & personality changes with memory loss:",
    "option_a": "FTD",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Frontotemporal dementia (FTD) is a neurodegenerative disorder primarily affecting the frontal and anterior temporal lobes. It is characterized by changes in personality, behavior, and language. In many cases, patients develop abnormal eating behaviors like hyperphagia, alongside personality changes. Although memory loss may occur, it is typically a later feature compared to the marked behavioral changes. FTD is associated with the accumulation of abnormal proteins such as tau or TDP-43 in neurons, leading to neuronal degeneration particularly in the frontal and temporal regions. Genetic factors play a role, with mutations in genes like MAPT and GRN identified in familial cases. Research continues to define the molecular pathways leading to neuronal loss and synaptic dysfunction. Patients with FTD often present with early disinhibition, apathy, compulsive behaviors, and changes in eating habits (eg, hyperphagia). Memory impairment tends to be less prominent at first compared to Alzheimer\u2019s disease. This clinical profile differentiates FTD from other dementias where memory loss is an early and defining feature. The diagnosis is based on clinical history, neuropsychological testing, and neuroimaging (MRI or PET scan) showing selective atrophy of the frontal and/or temporal lobes. Differential diagnoses include Alzheimer\u2019s disease (which presents primarily with early memory loss), major depressive disorder, and other psychiatric conditions. Biomarkers and genetic testing may also be used in selected cases. There is no cure for FTD. Management focuses on symptomatic treatment and supportive care. First-line management often involves behavioral and environmental modifications, and second-line options may include selective serotonin reuptake inhibitors (SSRIs) to manage behavioral symptoms. Antipsychotics may be used with caution. For pregnant or lactating patients (though rare given the typical age group), careful evaluation of the risk\u2013benefit ratio is essential before initiating any psychotropic medication. Option A (FTD) is correct because the presence of hyperphagia and personality changes fits the behavioral variant of FTD. Other options were not provided, but common distractors might include Alzheimer\u2019s disease (which presents with early memory loss rather than marked behavioral changes) or other neuropsychiatric conditions. 1. Hyperorality and changes in eating behavior are key features of FTD. 2. Early personality and behavioral changes, with relative sparing of memory initially, differentiate FTD from Alzheimer\u2019s disease. 3. Genetic mutations (MAPT, GRN) are often implicated in familial FTD. Recent studies emphasize the role of advanced neuroimaging and cerebrospinal fluid biomarkers in distinguishing FTD from other dementias. Ongoing genetic research is further clarifying the heterogeneity of this disorder, which may lead to more targeted therapies in the future.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "question about SCHAFFER collateral what is it?",
    "option_a": "Entorhinal cortex to Ca1",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "The Schaffer collaterals are a set of axonal projections within the hippocampus. They specifically connect the pyramidal neurons in the CA3 region to neurons in the CA1 region, playing a key role in the hippocampal circuitry involved in learning and memory. At a cellular level, the Schaffer collaterals are critical for synaptic transmission and are a primary site for the study of long-term potentiation (LTP), a cellular model of learning and memory. Disruption in these synaptic pathways can impair the encoding and consolidation of memory. Because the hippocampus is central to memory formation, any dysfunction in the Schaffer collateral pathway may contribute to memory deficits. However, these collaterals are typically not directly evaluated in clinical practice but are important in basic neuroscience research and in understanding the pathophysiology of memory disorders. Schaffer collateral function is usually assessed in experimental settings using electrophysiological techniques. Differential anatomy is important: for example, the perforant pathway connects the entorhinal cortex to the dentate gyrus and CA regions, which is distinct from the Schaffer collateral projections. There is no direct management targeting the Schaffer collaterals as they are an anatomical feature. However, understanding hippocampal circuitry is important when managing conditions that affect memory function, such as epilepsy or neurodegenerative diseases. In pregnant and lactating patients, caution is advised when utilizing any drugs that affect central neurotransmission, but this is generally not applicable for an anatomical structure like the Schaffer collaterals. Option A describes a connection from the entorhinal cortex to CA1, which actually pertains to the perforant pathway rather than the Schaffer collaterals. The marked answer (Option B) is assumed to correctly represent the projection from CA3 to CA1, making it the correct choice. 1. Schaffer collaterals are essential in mediating synaptic transmission between CA3 and CA1, a critical step in memory formation. 2. They are a standard model for studying long-term potentiation (LTP) in neuroscience research. Recent research continues to investigate the molecular mechanisms underlying LTP and synaptic plasticity in the Schaffer collaterals, which may provide insights into novel treatments for memory impairments and neurodegenerative disorders.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "60 years old professor in university started to forget things, & loses his bank cards frequently but it not affecting his job, the patient was worried about his memory, what is the Dx:",
    "option_a": "Mild cognitive impairment.",
    "option_b": "Alzheimer disease.",
    "option_c": "Frontotemporal dementia",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Mild Cognitive Impairment (MCI) is a clinical condition characterized by cognitive decline greater than expected for a patient\u2019s age and educational background, yet not severe enough to interfere significantly with daily life or independent function. MCI is considered a transitional state between normal aging and dementia. Structural and functional changes, such as hippocampal atrophy and decreased cholinergic transmission, are often observed. MCI can be a precursor to Alzheimer\u2019s disease or other dementias, though not all cases progress. In the scenario of a 60-year-old professor who experiences forgetfulness (e.g., misplacing bank cards) without impairment in professional or daily functioning, the cognitive deficits are noticeable but not debilitating. This profile is typical for MCI, where the individual remains aware and concerned about their memory yet maintains independence. Diagnosis involves clinical evaluation, neuropsychological testing, and sometimes neuroimaging. Differential diagnoses include early Alzheimer\u2019s disease (which usually leads to impaired daily functioning), depression-related cognitive impairment, and age-associated memory impairment. It is important to distinguish MCI from normal aging and established dementia. The management of MCI centers on lifestyle modifications, cognitive rehabilitation, and risk factor control. First-line management includes regular monitoring, physical exercise, cognitive training, and management of comorbidities. Pharmacological treatments (eg, cholinesterase inhibitors) are not routinely recommended in MCI but may be considered in research settings. In pregnancy and lactation, precautionary counseling is important if medications are ever considered, though lifestyle interventions are typically safer. Option A (Mild Cognitive Impairment) is correct because the patient\u2019s symptoms \u2013 noticing occasional forgetfulness without significant impact on daily functioning \u2013 align with the definition of MCI. Option B (Alzheimer disease) is less likely because Alzheimer\u2019s usually presents with more functionally impairing memory loss. Option C (Frontotemporal dementia) would typically involve more prominent behavioral and personality changes rather than isolated memory lapses. 1. MCI represents a state of cognitive decline that does not interfere significantly with daily life, distinguishing it from dementia. 2. Patients with MCI are at an increased risk for progression to Alzheimer\u2019s disease, especially in the amnestic subtype. 3. Regular follow-up and cognitive evaluation are crucial to monitor progression. Current guidelines emphasize non-pharmacologic interventions and risk factor modification as the mainstay of MCI management. Emerging research focuses on biomarkers and imaging techniques to predict which cases are most likely to progress to dementia.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "50 years old male pt had history of cognitive impairment for 6 months with depression and abnormal movement And his father died at the age of 60 years with I think depression (HUNTINGTON DISEASES) What is the gene??",
    "option_a": "CAG REPEAT",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Huntington's disease is an autosomal dominant neurodegenerative disorder characterized by a triad of motor dysfunction (typically chorea), cognitive decline, and psychiatric disturbances. It has a well-established genetic basis. The disease is caused by an expansion of a CAG trinucleotide repeat in the HTT gene on chromosome 4. This expansion leads to an abnormally long polyglutamine tract in the huntingtin protein, resulting in protein misfolding, neuronal toxicity, and eventual cell death. There is a phenomenon of anticipation, wherein the number of repeats can increase in successive generations, leading to earlier onset and more severe manifestations. Clinically, patients present with gradual onset of motor abnormalities, cognitive impairment, and psychiatric symptoms such as depression. A positive family history, as described in the case, supports the diagnosis. The presence of abnormal movements (chorea) along with cognitive and psychiatric symptoms is highly indicative of Huntington's disease. The diagnosis is confirmed through genetic testing for the CAG trinucleotide repeat expansion in the HTT gene. Differential diagnoses include other causes of chorea (such as Wilson disease, neuroacanthocytosis, and drug-induced dyskinesias) and other neurodegenerative conditions with psychiatric manifestations. A detailed family history is crucial. There is currently no cure for Huntington's disease; management is symptomatic and multidisciplinary. First-line treatment for chorea includes medications such as tetrabenazine or deutetrabenazine, while antipsychotics and SSRIs may be used for psychiatric symptoms. Cognitive therapies and supportive care are integral. In pregnancy and lactation, genetic counseling is paramount, and treatment choices must carefully weigh maternal benefits against potential fetal risks. Close collaboration with maternal\u2013fetal medicine specialists is recommended. Option A (CAG Repeat) is correct because Huntington's disease is caused by an expanded CAG repeat in the HTT gene. Other options (though not listed) might include different gene mutations relevant to other conditions, making Option A the only appropriate choice. 1. Huntington's disease demonstrates genetic anticipation, meaning symptoms may present at an earlier age in successive generations. 2. A detailed family history is essential in suspecting and diagnosing the disorder. 3. The triad of motor, cognitive, and psychiatric symptoms is classic for Huntington's disease. Recent advances include ongoing research into gene-silencing techniques and other targeted therapies that may modify the disease course. Guidelines continue to underscore the importance of multidisciplinary management and early genetic counseling, particularly for individuals of childbearing age.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Elderly pt with temporal pain, jaw claudication and visual symptoms high ESR ? Next?",
    "option_a": "Iv methylpred",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "This case describes an elderly patient with new-onset temporal pain, jaw claudication, visual symptoms and a markedly elevated ESR \u2013 a classic presentation of giant cell (temporal) arteritis. The underlying principle is that the inflammation of medium\u2010to\u2010large arteries (especially the temporal artery) can lead to ischemia and, when it affects the ophthalmic circulation, it poses an immediate risk of permanent vision loss. Giant cell arteritis is driven by a T-cell\u2013mediated immune response leading to granulomatous inflammation in the arterial wall with giant cell formation, intimal thickening, and subsequent luminal narrowing. The reduced blood flow, especially to the optic nerve, is the key mechanism behind the visual disturbances. The process involves cytokine release (e.g., IL\u20106) and can lead to irreversible infarction if untreated. Clinically, patients present with unilateral temporal headache, scalp tenderness, jaw claudication, and possibly blurred vision or even sudden vision loss. The high ESR further supports an intense inflammatory process. Prompt recognition of these signs is critical because delay in treatment, especially in the presence of visual symptoms, can result in permanent blindness. The diagnosis is primarily clinical, supported by laboratory tests such as markedly elevated ESR and CRP. Temporal artery biopsy remains the gold standard for confirmation, although treatment should not be delayed while awaiting biopsy results. Differential diagnoses include migraine, tension-type headache, or other systemic vasculitides; however, the association with jaw claudication and high inflammatory markers is more specific for GCA. The current standard of care is immediate initiation of high-dose corticosteroids to prevent further ischemic damage, particularly vision loss. In patients with visual involvement, intravenous (IV) methylprednisolone is recommended (typically 1 gram daily for 3 days) followed by a transition to high-dose oral prednisone. In pregnant or lactating patients\u2014though rare in this age group\u2014the benefits of corticosteroid therapy in GCA far outweigh the potential risks, and careful monitoring with the minimal effective dose is advised. Option A (IV methylprednisolone) is correct because immediate, high-dose corticosteroid therapy is essential in patients with visual symptoms to prevent irreversible vision loss. Other options (not provided) that might delay therapy or suggest lower-dose treatment would be inappropriate in this urgent setting. 1. Always treat suspected GCA immediately with corticosteroids if visual symptoms are present. 2. Jaw claudication is a highly specific symptom. 3. Temporal artery biopsy can be performed after initiating steroids without significantly affecting the diagnostic yield. Recent guidelines and research continue to support early aggressive corticosteroid therapy in GCA to prevent blindness. There is also emerging evidence regarding the use of adjunctive therapies like tocilizumab for refractory cases, but in the setting of visual involvement, immediate high-dose steroids remain the cornerstone of therapy.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "60 years old male pt had visual loss and he denied that. in the examination he had a visual field defect, what is the diagnosis?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Dementia",
    "explanation": "This question highlights a unique neurological phenomenon in which a patient with an objective visual field defect denies any visual loss. This lack of insight into one's own deficit is known as visual anosognosia, which is often encountered in cortical blindness (Anton syndrome). Visual anosognosia is typically the result of bilateral occipital lobe damage (or damage to the visual association areas), where the patient\u2019s brain is unable to accurately process visual information or recognize the deficit. Despite the lack of visual perception, the patient may confabulate or deny the visual loss due to disconnection between visual processing areas and self-awareness networks. The patient presents with a visual field defect on examination, yet he denies any problems with his vision. This dissociation between objective findings and subjective awareness is a hallmark of visual anosognosia, commonly seen in cases of cortical blindness. Differential diagnoses include: 1) Acalculia, which is a numeric processing difficulty; 2) Agraphia, which is an inability to write; and 3) Optic ataxia, which is a visuomotor control disorder. Neuroimaging (MRI or CT) typically reveals occipital or parietal lesions that help confirm the diagnosis of visual anosognosia, often under the umbrella of Anton syndrome. Management of visual anosognosia primarily involves addressing the underlying cause (e.g., stroke management if an infarct is responsible) and supportive therapy including rehabilitation. There is no direct pharmacological treatment for anosognosia. In cases where stroke is the etiology, standard stroke protocols (which consider pregnancy and lactation by balancing risks and benefits of imaging and interventions) should be followed. Option 1 (Acalculia) is incorrect because it refers to numerical deficits and is unrelated to visual denial. Option 2 (Agraphia) is unrelated as it involves writing deficits. Option 3 (Optic ataxia) is a visuomotor impairment that does not involve denial of vision. Option 4 (Visual anosognosia) is correct as it accurately describes a condition in which the patient is unaware of his visual impairment, which matches the clinical picture. 1. Anton syndrome is characterized by cortical blindness with denial of the visual deficit. 2. Brain lesions affecting the occipital lobes are typically responsible. 3. Awareness of deficits can be compromised in focal brain injuries, leading to anosognosia. Recent neuroimaging studies have improved understanding of the neural mechanisms behind anosognosia, showing disrupted connectivity in awareness networks. Emerging research continues to explore targeted rehabilitation strategies to help improve patient insight into their deficits.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Pt w word finding difficulty, behavioral changes\u2026 dx?",
    "option_a": "pick's disease",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "This question presents a patient with word-finding difficulty and behavioral changes\u2014features that are characteristic of frontotemporal dementia variants. Pick's disease is a historical term often used to denote a subtype of frontotemporal dementia (FTD) particularly associated with prominent language disturbances and behavioral abnormalities. Pick's disease is marked by the accumulation of tau protein in the form of Pick bodies, leading to neuronal degeneration and selective atrophy in the frontal and temporal lobes. This proteinopathy disrupts normal neuronal functioning, resulting in language deficits, personality changes, and executive dysfunction. Patients with Pick's disease typically present with gradual personality changes, social disinhibition, apathetic behavior, and language abnormalities including word-finding difficulties. These symptoms correlate with the degeneration of brain regions responsible for behavior and language, and imaging usually reveals frontotemporal atrophy. The differential diagnosis includes Alzheimer\u2019s disease (which usually presents with memory impairment rather than early behavioral or language changes), vascular dementia, and psychiatric disorders. Neuropsychological testing and neuroimaging\u2014typically an MRI showing frontal and temporal atrophy\u2014aid in distinguishing Pick's disease from other dementias. There is currently no disease-modifying treatment for Pick's disease. Management is symptomatic and supportive, including the use of SSRIs to manage behavioral symptoms and speech therapy to help with language difficulties. Given its prevalence in middle-aged to elderly patients, pregnancy and lactation considerations are less relevant; however, management remains supportive and interdisciplinary. Option A (Pick's disease) is correct because the combination of word-finding difficulty and behavioral changes is most typical of a frontotemporal dementia variant, classically represented by Pick's disease. Other options (not provided) would likely not account for both the language and the behavioral components inherent to this disease. 1. Early behavioral changes coupled with language deficits suggest a diagnosis of frontotemporal dementia. 2. MRI findings of frontal and/or temporal atrophy support the diagnosis. 3. Pick's disease is pathologically defined by the presence of tau-positive Pick bodies. Current research focuses on improving diagnostic biomarkers for FTD, including tau PET imaging and cerebrospinal fluid assessments. While there remains no cure, ongoing clinical trials are investigating potential disease-modifying therapies that target tau pathology.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Male patient with recent behavioral changes with MRI showing frontal and temporal atrophy:",
    "option_a": "FTD",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "This patient presents with recent behavioral changes and MRI evidence of frontal and temporal atrophy. This clinical picture is classic for frontotemporal dementia (FTD), a neurodegenerative disorder primarily affecting the frontal and temporal lobes. FTD is characterized by selective neuronal degeneration in the frontal and temporal lobes, often associated with abnormal protein accumulations such as tau (as seen in Pick\u2019s disease) or TDP-43. The loss of neurons in these regions leads to deficits in behavior, personality, and language. Behavioral variant FTD typically presents with changes in social conduct, disinhibition, apathy, and executive dysfunction. MRI findings of frontal and temporal atrophy confirm the diagnosis and distinguish it from other dementias like Alzheimer\u2019s disease, which generally exhibits a more prominent temporoparietal atrophy pattern. Differential diagnoses include late-onset psychiatric disorders and Alzheimer\u2019s dementia. Neuropsychological testing, combined with neuroimaging (MRI), is crucial for differentiating FTD from these conditions. The clinical history of rapidly evolving behavioral changes with corresponding imaging findings is highly suggestive of FTD. Currently, there is no cure for FTD, and treatment is largely supportive. Management strategies include behavioral interventions, occupational therapy, and symptomatic pharmacotherapy (such as SSRIs for behavioral symptoms). While FTD is typically a disorder of the elderly, in the rare instance of a younger patient (or if similar symptoms are encountered in a pregnant patient under very exceptional circumstances), management would still focus on supportive care with attention to the safety profile of medications during pregnancy or lactation. Option A (FTD) is correct because the combination of recent behavioral changes and MRI findings of frontal and temporal atrophy is the hallmark for frontotemporal dementia. Other options (if provided) would not be as consistent with the imaging and clinical presentation described. 1. Behavioral changes and disinhibition are key features of the behavioral variant of FTD. 2. MRI findings demonstrating frontal and temporal atrophy are critical in substantiating the diagnosis. 3. Unlike Alzheimer\u2019s disease, memory is relatively preserved in the early stages of FTD. Emerging research is focused on identifying biomarkers for earlier diagnosis and exploring potential tau-targeting therapies. Although no disease-modifying treatments exist, ongoing clinical trials and advances in neuroimaging continue to enhance our understanding of FTD.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Male patient 85 YO presenting can walk but with gait freezing, cognitive changes, bradykinesia and urinary incontinence, image (only report): showed ventriculomegaly (moderate) and mild brain atrophy: (NPH)",
    "option_a": "Start levodopa",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Normal Pressure Hydrocephalus (NPH) is characterized by the classic triad of gait disturbance (typically a magnetic, shuffling gait or gait freezing), cognitive impairment, and urinary incontinence. It is classified as a form of communicating hydrocephalus where the cerebrospinal fluid (CSF) dynamics are disturbed without a significant increase in CSF pressure. In NPH, there is impaired CSF absorption at the arachnoid granulations leading to an accumulation of CSF that preferentially enlarges the ventricular system (ventriculomegaly). This expansion exerts pressure on the periventricular white matter, disrupting neuronal function, particularly in areas controlling gait and bladder functions. Recent studies emphasize the role of dynamic CSF flow studies and tap test responsiveness in confirming the diagnosis. The patient\u2019s age and symptom triad (gait freezing, cognitive changes, and urinary incontinence) align with the classic presentation of NPH. Although some features may mimic Parkinson\u2019s disease (e.g., bradykinesia), the urinary incontinence and imaging showing ventriculomegaly in the absence of marked CSF pressure elevation help differentiate NPH from other motor neurodegenerative conditions. Diagnosis is primarily clinical supported by neuroimaging (CT or MRI) which in NPH typically reveals ventriculomegaly out of proportion to cortical atrophy. The differential diagnosis includes Parkinson\u2019s disease (which shows improvement with levodopa), Alzheimer\u2019s disease, and vascular dementia. A high-volume lumbar tap test, sometimes with extended CSF drainage monitoring, is used to predict responsiveness to shunt placement. First-line management involves performing a high-volume lumbar puncture (tap test) to assess improvement in symptoms. If positive, the definitive treatment is typically the placement of a ventriculoperitoneal (VP) shunt. Second-line measures include supportive therapies and rehabilitation. In the rare cases where NPH occurs during pregnancy or lactation, a detailed risk-benefit discussion is essential, although these scenarios are uncommon. Option A (Start levodopa) is incorrect because levodopa is indicated for Parkinson\u2019s disease, not NPH. The marked answer, Option B (implied to be CSF diversion, such as a VP shunt after a positive tap test), is correct as it directly addresses the underlying CSF circulation problem in NPH. 1) Always consider NPH in elderly patients presenting with gait instability, cognitive decline, and urinary incontinence. 2) A positive response to a lumbar tap test is highly suggestive of shunt-responsive NPH. 3) Differentiating NPH from Parkinson\u2019s disease is crucial since treatment pathways greatly differ. Current guidelines emphasize the utility of neuroimaging combined with CSF dynamics assessments in diagnosing NPH. Recent research supports early intervention with shunt placement to reverse or stabilize neurological decline, and careful patient selection based on tap test responsiveness is endorsed by neurosurgical guidelines.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Pt w hx of change in memory forgetting things and CSF showed high tau protein low amyloid dx?",
    "option_a": "AD\u2026",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer\u2019s Disease (AD) is a neurodegenerative disorder primarily characterized by progressive memory impairment. In the context of CSF biomarkers, AD typically shows a pattern of decreased amyloid beta (A\u03b242) and increased tau protein levels. AD is driven by the accumulation of amyloid plaques and tau neurofibrillary tangles that promote synaptic dysfunction and neuronal death. Elevated tau protein, including its phosphorylated forms, reflects neuronal injury and degeneration. The CSF biomarker profile (low A\u03b242 and high tau) is considered highly specific for AD pathology. Patients with AD generally present with gradual, progressive memory loss, particularly affecting recent or short-term memory. This presentation, combined with the CSF profile showing high tau and low amyloid beta, strongly supports a diagnosis of AD. The diagnostic workup for dementia includes clinical evaluation, neuropsychological testing, and neuroimaging. Differential diagnoses include vascular dementia (often with stepwise declines and focal neurologic findings), Lewy body dementia (which may include visual hallucinations and parkinsonism), and frontotemporal dementia (typically with personality or language changes). CSF analysis and PET imaging for amyloid deposition are used to confirm AD. First-line pharmacologic management includes cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and, in moderate to advanced stages, NMDA receptor antagonists (memantine). Non-pharmacologic interventions like cognitive therapy and lifestyle modifications are important. In cases of pregnancy or lactation, the use of these medications must be carefully evaluated against potential risks, and alternative symptomatic management may be considered. Option A (AD) is correct because the CSF findings of high tau and low amyloid beta are hallmark laboratory features of Alzheimer\u2019s Disease, matching the patient\u2019s clinical presentation of memory impairment. 1) The typical CSF biomarker pattern in AD is decreased A\u03b242 with elevated tau and phosphorylated tau levels. 2) Progressive short-term memory loss is often the earliest symptom in AD. 3) Differential diagnosis should consider clinical history and corroborative neuroimaging findings. Recent research supports the use of CSF biomarkers and amyloid PET imaging for early AD diagnosis. Updated guidelines encourage integrating clinical findings with biomarker profiles to improve diagnostic accuracy and guide early therapeutic interventions.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "This is 70 yo female with history of short term memory impairment with DLAs, long term memory not affected, depression withdrawal from people. CSF amyloid low, Tua positive. what is the diagnosis:",
    "option_a": "FTD",
    "option_b": "AD",
    "option_c": "DLB",
    "option_d": "CBD",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer\u2019s Disease (AD) is typically characterized by early impairment in short-term memory while long-term memory may remain relatively preserved during the initial phases. CSF biomarkers such as low amyloid beta and elevated tau proteins further support this diagnosis. In AD, the pathological accumulation of amyloid beta leads to plaque formation and the hyperphosphorylation of tau leads to neurofibrillary tangles, both of which contribute to synaptic dysfunction and neuronal death. The CSF profile\u2014low amyloid beta with high tau\u2014is indicative of these underlying processes. This 70-year-old female\u2019s presentation with short-term memory impairment, preserved long-term memory in early stages, and symptoms like social withdrawal (which may be secondary to cognitive changes) aligns with early AD. The CSF biomarker findings further support the diagnosis, as they mirror the classical AD profile. Differential diagnoses for dementia include frontotemporal dementia (FTD), which typically presents with prominent personality or language changes; dementia with Lewy bodies (DLB), usually marked by visual hallucinations and parkinsonian features; and corticobasal degeneration (CBD), which presents with asymmetric motor deficits and apraxia. Neuropsychological testing, imaging (MRI, PET), and CSF studies help differentiate these conditions. The mainstay of AD treatment involves the use of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) as first-line therapy, with memantine added in moderate-to-severe cases as a second-line agent. Non-pharmacologic measures including cognitive rehabilitation, exercise, and diet modifications are also recommended. In pregnant or lactating patients, the safety profiles of these medications require careful evaluation, and detailed counseling on risks versus benefits is crucial. Option A (FTD) is less likely because FTD usually affects executive function and behavior more distinctly rather than the isolated short-term memory impairment seen here. Option B (AD) is most consistent with the patient\u2019s clinical presentation and CSF findings. Option C (DLB) and Option D (CBD) have other specific clinical and imaging features that are not present in this case. 1) Early AD primarily affects short-term memory while long-term memory can be spared in the early stages. 2) CSF biomarkers (decreased amyloid beta and increased tau) are critical in supporting the diagnosis of AD. 3) Differential diagnosis should integrate both clinical and biochemical findings. Recent guidelines advocate the use of CSF and imaging biomarkers for early AD diagnosis. Continuous research is focused on disease-modifying therapies, but current management still centers on symptomatic treatment and supportive care, with ongoing studies evaluating their efficacy in various populations including special groups like pregnant or lactating patients.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "Elderly patient presented with visual field defect but she denied, she had left homogenous hemianopia. CT brain done. What is the explanation of her issue:",
    "option_a": "Visual anosognosia",
    "option_b": "Psychiatric",
    "option_c": "Apraxia",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Visual anosognosia refers to the phenomenon wherein a patient is unaware of or denies the presence of a visual deficit despite objective evidence. This is often seen in conditions involving cortical visual impairment, such as with lesions in the occipital lobe (Anton syndrome being an extreme example). Damage to the visual cortex or associated neural pathways not only causes a loss in the visual field (e.g., homonymous hemianopia) but can also disrupt the patient\u2019s awareness of the deficit. This dissociation between objective visual loss and the patient\u2019s subjective experience is characteristic of anosognosia. In this case, the left homogenous hemianopia is present on imaging, yet the patient denies any visual problems. An elderly patient with a CT-documented left homonymous hemianopia who denies visual impairment exemplifies visual anosognosia. The disconnect between the neurologic deficit and the patient\u2019s acknowledgment supports this diagnosis rather than a psychiatric cause. When encountering visual field deficits, differential diagnoses include psychiatric disorders (where denial might be seen, but usually not in the context of a clear neurologic deficit), visual neglect (commonly associated with right parietal lesions), and apraxia (which relates to motor planning deficits rather than sensory loss). Comprehensive neuroimaging and neuropsychological evaluations help clarify the diagnosis. Management primarily involves patient education and visual rehabilitation strategies, often with the help of occupational therapy to compensate for visual field deficits. There is no specific pharmacologic treatment. In a pregnant or lactating patient, management would still be supportive, with the emphasis on safe, non-pharmacologic therapies. Option A (Visual anosognosia) is correct because it accurately describes a situation in which the patient denies a confirmed visual field deficit. Option B (Psychiatric) is less appropriate in the absence of primary psychiatric symptoms. Option C (Apraxia) refers to a motor planning issue and does not explain the denial of a visual deficit. 1) Anosognosia is a common finding in patients with cortical visual impairments and can be mistaken for psychiatric denial. 2) Always correlate imaging findings with clinical examination in cases of visual deficits. 3) Recognition of anosognosia can influence rehabilitation strategies and patient counseling. Contemporary studies continue to explore the neural mechanisms underlying anosognosia, emphasizing the role of right hemispheric and occipital lobe dysfunction. Current guidelines advocate for a multidisciplinary approach involving neurology, neuropsychology, and rehabilitation specialists to optimize outcomes for patients with cortical visual impairments.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "This is 58 yo female presented change is her behaviors, memory issue, visual hallucinations, MRI showed frontal atrophy, peraital atrophy, what is the diagnosis:",
    "option_a": "FTD",
    "option_b": "AD",
    "option_c": "DLB",
    "option_d": "CBD",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Dementia",
    "explanation": "Dementia with Lewy Bodies (DLB) is one of the common neurodegenerative dementias. Its core features include fluctuating cognition, recurrent visual hallucinations, and signs of parkinsonism. Although memory issues can be present, early on it is the hallucinations and cognitive fluctuations that often direct the diagnosis. DLB is characterized by the deposition of alpha\u2010synuclein protein in cortical and subcortical regions. This deposition most notably affects areas involved in visuoperceptual processing, which explains the occurrence of visual hallucinations. Although MRI may not present with dramatic atrophy early in the disease, as the disease progresses, some degree of atrophy (sometimes involving frontal and parietal regions) may be seen. In patients with DLB, visual hallucinations are one of the hallmark features and are often vivid and well formed. Memory impairment may be mild or fluctuate, and patients can also exhibit behavioral changes. This contrasts with Alzheimer\u2019s disease where memory deficits are predominant and visual hallucinations are not typical early on. The diagnosis relies on clinical criteria (such as the McKeith criteria) and supportive features. Differential diagnoses include Alzheimer\u2019s disease (characterized by predominant medial temporal and parietal atrophy with prominent memory loss), frontotemporal dementia (with marked behavioral changes but less frequent hallucinations), and corticobasal degeneration (which usually presents with asymmetric motor features). Additional investigations like dopamine transporter (DAT) SPECT imaging can be useful in supporting a diagnosis of DLB. Management is largely symptomatic. First-line management includes cholinesterase inhibitors (e.g., rivastigmine), which can help with cognition and hallucinations. It is also crucial to avoid typical antipsychotics due to increased sensitivity in DLB patients. Nonpharmacological strategies and supportive measures are important. Although DLB usually occurs in older patients, if a patient were to be pregnant or lactating (a very rare scenario in this context), treatment modifications and careful risk\u2013benefit evaluations would be required, with multidisciplinary consultation. Option A (FTD) is typically marked by early and prominent personality changes with relatively spared memory and lacks visual hallucinations. Option B (AD) typically involves medial temporal and parietal atrophy and presents with prominent memory impairment but less with early visual hallucinations. Option D (CBD) usually presents with asymmetric motor findings and apraxia. Option C (DLB) is correct given the presence of visual hallucinations and the neurodegenerative profile, even if the atrophy pattern is not pathognomonic. 1) Visual hallucinations in an older patient with fluctuating cognition should raise suspicion for DLB. 2) Sensitivity to neuroleptics is a characteristic hazard in DLB. 3) Imaging studies may be less striking early in DLB but clinical features are key for diagnosis. Recent research emphasizes the use of cholinesterase inhibitors for symptomatic management and supports the role of DAT imaging for diagnostic clarity. Updated guidelines stress careful medication use given neuroleptic sensitivity and advocate for a multidisciplinary approach to management.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "This is 56 yo female, her family complain about her behavior and change in her personality, she start talking to strangers, she receive warning from work because of inappropriate sexual jokes, she has poor hygiene of her self, MME 28/30, what is the diagnosis:",
    "option_a": "FTD",
    "option_b": "AD",
    "option_c": "LBD",
    "option_d": "Vascular dementia",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Frontotemporal Dementia (FTD) is a neurodegenerative disorder that primarily affects the frontal and temporal lobes, leading to marked changes in behavior, personality, and language. The behavioral variant of FTD is most common and is characterized by disinhibition, apathy, loss of empathy, and socially inappropriate behavior. FTD involves degeneration of the frontal and anterior temporal lobes. Abnormal protein accumulations such as tau or TDP-43 are frequently implicated. These pathologic changes disrupt neural circuits responsible for executive function and social comportment, leading to the behavioral symptoms observed. The patient\u2019s presentation \u2013 marked personality changes, inappropriate social behavior (such as talking to strangers and making sexual jokes), poor self-care, while retaining a near-normal MMSE score (28/30) \u2013 is highly characteristic of behavioral variant FTD. Unlike Alzheimer\u2019s disease, memory and orientation are often relatively preserved until later stages in FTD. FTD is a clinical diagnosis supported by neuroimaging which typically shows frontal (and sometimes temporal) atrophy. Differential diagnoses include Alzheimer\u2019s disease (which usually presents with early memory deficits), psychiatric disorders (like bipolar disorder or personality disorders), and vascular dementia (which typically has a stepwise progression). Detailed neuropsychological testing and structural imaging (MRI) aid in distinguishing these conditions. There is no cure for FTD. Management is generally supportive and focuses on behavioral control. First-line approaches include nonpharmacological interventions and caregiver support. Selective serotonin reuptake inhibitors (SSRIs) may be used to mitigate behavioral symptoms. In the context of pregnancy or lactation (which is rarely encountered in FTD given the usual age of onset), medication safety must be reviewed on a case-by-case basis, ideally with consultation from specialists in maternal\u2013fetal medicine. Option A (FTD) is correct, given the clinical picture with behavioral disinhibition and personality change. Option B (AD) typically presents with marked memory impairment rather than profound changes in social behavior. Option C (LBD) is more consistent with visual hallucinations and parkinsonism, and Option D (Vascular Dementia) typically features a stepwise decline with focal neurological deficits. 1) In bvFTD, memory and orientation may remain intact even in the presence of dramatic behavioral changes. 2) Early behavioral disinhibition and loss of social decorum are key clues to FTD. 3) Structural MRI often reveals frontal lobe atrophy, providing supportive evidence for the diagnosis. Recent literature emphasizes early recognition of FTD due to its distinct behavioral profile, and ongoing research is investigating genetic markers (such as C9orf72 mutations) which can inform prognosis and counseling. Guidelines continue to advocate for nonpharmacologic management and caregiver education as mainstays of treatment.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "2nd most common neurodegenerative Dementia is",
    "option_a": "(Lewy Body Dementia) is third in prevalence and is characterized by features not described in the question. Option B (Frontotemporal Dementia) is less common and usually affects younger patients. Option C (Alzheimer\u2019s Disease) is the most common dementia, not the second. Option D (Vascular Dementia) is correct because epidemiological studies consistently identify VaD as the second most prevalent neurodegenerative cause of dementia.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "d",
    "subspecialty": "Dementia",
    "explanation": "Neurodegenerative dementias are commonly ranked by prevalence. Alzheimer\u2019s disease (AD) is the most common, and vascular dementia (VaD) is widely recognized as the second most common type, especially when considering mixed pathologies in the elderly. Vascular dementia results from cumulative cerebrovascular insults\u2014ranging from large strokes to multiple microinfarcts\u2014which lead to impaired cerebral blood flow and subsequent cognitive impairment. The pathology is linked to underlying vascular risk factors such as hypertension, diabetes, and atherosclerosis. Patients with vascular dementia often exhibit a stepwise decline in cognitive function, with episodes of sudden worsening that coincide with cerebrovascular events. Executive dysfunction is typical, and impairment in attention and planning is common. This distinguishes it from Alzheimer\u2019s disease, which typically presents with a gradual, insidious decline. Diagnosis is based on clinical history, neuroimaging (CT/MRI showing evidence of infarcts or white matter changes), and the presence of vascular risk factors. Differential diagnoses include Alzheimer\u2019s disease (which shows a more gradual memory decline), Lewy Body Dementia (characterized by visual hallucinations and parkinsonism), and Frontotemporal Dementia (marked by behavioral changes). Management involves aggressive control of vascular risk factors \u2013 such as hypertension, diabetes, and hyperlipidemia \u2013 to prevent further cerebrovascular events. First-line management includes lifestyle modifications and pharmacologic therapies (antihypertensives, antiplatelet agents). Second-line interventions may be considered for stroke prevention in high-risk individuals. Although rare in the typical age group for VaD, in the event of a pregnant or lactating patient with vascular risk, treatment would need careful tailoring with the safest agents after consultation with obstetrical specialists. Option A (Lewy Body Dementia) is third in prevalence and is characterized by features not described in the question. Option B (Frontotemporal Dementia) is less common and usually affects younger patients. Option C (Alzheimer\u2019s Disease) is the most common dementia, not the second. Option D (Vascular Dementia) is correct because epidemiological studies consistently identify VaD as the second most prevalent neurodegenerative cause of dementia. 1) Vascular risk factor management is essential in preventing further cognitive decline in patients with vascular dementia. 2) A stepwise decline in cognitive function is a hallmark of vascular dementia. 3) Neuroimaging is critical in differentiating vascular dementia from other subtypes of dementia. Recent guidelines emphasize the importance of controlling vascular risk factors to prevent or slow the progression of vascular dementia. Research also supports the use of multimodal imaging techniques for early detection and differentiation from other forms of dementia, and current best practices advocate a multidisciplinary approach in management.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient with increasing forgetfulness, he had to change his Bank ATM card because he miss placed it. On effect on his ADLS and his doing good at work",
    "option_a": "(MCI) is correct because the patient demonstrates memory lapses without significant impairment in ADLs or work performance. Option B (Dementia) is incorrect since dementia involves functional impairment that is not present in this scenario.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Dementia",
    "explanation": "Mild Cognitive Impairment (MCI) is defined as the cognitive decline that is greater than expected for an individual\u2019s age and education level but does not interfere significantly with daily activities or functional independence. It is considered to be an intermediate stage between normal aging and dementia. MCI may represent early pathologic changes (such as incipient Alzheimer\u2019s disease) or other causes of cognitive decline. Neuropathological changes can include a lower burden of amyloid plaques or neurofibrillary tangles compared to full-blown dementia, along with subtle synaptic dysfunction. The patient\u2019s presentation \u2013 increasing forgetfulness, such as misplacing an ATM card \u2013 in the setting of preserved work performance and independent activities of daily living, is typical of MCI. While the patient does show some memory lapses, his functional capacity remains intact, which is the key distinction from dementia. Diagnosis of MCI is largely clinical and involves demonstrating cognitive decline (usually in memory) without significant impairment of ADLs. Differential diagnoses include normal age-related memory loss, depression (pseudodementia), and early dementia. Detailed neuropsychological evaluations are used alongside clinical history and sometimes imaging to assess for potential progression. Management focuses on monitoring the progression of cognitive impairment with periodic evaluations. Lifestyle modifications, cognitive training, and managing cardiovascular risk factors are recommended. Pharmacologic treatments (like cholinesterase inhibitors) are generally not first-line for MCI except in research settings or select cases. Pregnancy and lactation considerations are generally not applicable in MCI given the typical age group; however, if encountered, any pharmacologic interventions would need careful review for safety in these populations. Option A (MCI) is correct because the patient demonstrates memory lapses without significant impairment in ADLs or work performance. Option B (Dementia) is incorrect since dementia involves functional impairment that is not present in this scenario. 1) A key feature of MCI is preserved independence in daily living despite subjective or objective memory complaints. 2) Close follow\u2010up is essential because a subset of MCI patients may progress to dementia. 3) Differentiating MCI from normal aging and early dementia is primarily based on functional assessment. Emerging research is focused on biomarkers for early detection of MCI and predicting conversion to Alzheimer\u2019s disease. Current guidelines recommend nonpharmacological interventions as first-line management, with an emphasis on managing modifiable risk factors and lifestyle changes.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "FTD case with frontal and temporal atrophy in MRI. About diagnosis?",
    "option_a": "Frontotemporal dementia",
    "option_b": "Alzheimer's disease",
    "option_c": "Vascular dementia",
    "option_d": "Lewy body dementia",
    "option_e": "Normal aging",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Frontotemporal dementia (FTD) is a group of neurodegenerative disorders characterized by progressive degeneration of the frontal and temporal lobes. It usually manifests with behavioral changes, language difficulties, or both. Neuroimaging typically shows focal atrophy in the frontal and/or temporal regions. FTD is associated with abnormal accumulation of proteins such as tau, TDP-43, or fused in sarcoma (FUS) in neurons. These proteinopathies lead to selective neuronal loss, synaptic dysfunction, and atrophy of the frontal and temporal lobes. Genetic mutations (eg, in MAPT, progranulin, or C9orf72) can predispose to this disease, and research continues to refine our understanding of its molecular mechanisms. Patients with FTD often present with significant personality and behavioral changes (disinhibition, apathy, compulsive behaviors) or language disturbances (primary progressive aphasia). Unlike Alzheimer\u2019s disease, memory is relatively spared in the early stages. The imaging findings of frontal and temporal lobe atrophy correlate well with these clinical deficits. Differential diagnoses include Alzheimer\u2019s disease (which primarily affects the memory and temporoparietal regions), vascular dementia (usually showing multi-infarct patterns and white matter changes), and Lewy body dementia (which may include visual hallucinations and parkinsonism). A detailed history, neuropsychological testing, and MRI findings are used to distinguish FTD from these conditions. There is currently no disease\u2010modifying treatment for FTD. Management primarily focuses on symptomatic control and behavioral management, often using SSRIs for disinhibition, antipsychotics in severe cases (with caution regarding side effects), and supportive therapies such as speech and occupational therapy. In pregnancy or lactation scenarios (rare for FTD due to typical age of onset), any pharmacotherapy would require a careful risk\u2013benefit analysis, but non\u2010pharmacologic support remains the mainstay. Option A (Frontotemporal dementia) is correct. Option B (Alzheimer's disease) tends to result in more diffuse atrophy predominantly in the temporoparietal regions with marked memory impairment. Option C (Vascular dementia) is associated with stepwise cognitive decline and white matter changes or discrete infarcts. Option D (Lewy body dementia) involves features like visual hallucinations and fluctuating cognition with parkinsonism. Option E (Normal aging) does not cause the degree of atrophy seen in FTD. 1. FTD typically presents before the age of 65 with marked behavioral or language symptoms. 2. In contrast to Alzheimer\u2019s disease, memory is relatively preserved in early FTD. 3. Neuroimaging plays a crucial role in differentiating FTD from other dementias. Recent research emphasizes genetic and molecular markers in FTD, and ongoing trials are targeting tau and TDP-43 aggregation. Current guidelines reinforce a symptomatic management approach and highlight the importance of a multidisciplinary team for care.",
    "exam_year": "2023",
    "exam_type": "Promotion",
    "image_url": "page_12.png"
  }
]